CAMK2A and myeloid sarcoma: There was a significant difference between these control samples and the MS population, suggesting that decreased levels of CAMK2A are likely not attributed to general neuroinflammatory pathways but rather, they are inherent to MS pathophysiology (Supplementary Fig. 2A).